À/À mice. Thus, decreasing CD19 + EVs holds high potential to improve the chemotherapeutic antitumor effect.
In Brief 
INTRODUCTION
Chemotherapy remains one of the most classic treatments for advanced cancers. Some chemotherapeutic agents are reported to enhance antitumor immunity through eliminating immunosuppressive cells or triggering the ''immunogenic cell death'' of tumor cells (Ghiringhelli et al., 2009; Mé nard et al., 2008) . However, chemotherapy has long been related to the induction of systemic immunosuppression (Rasmussen and Arvin, 1982) . Many chemotherapeutic agents are myelosuppressive and can inhibit the production of blood cells in the bone marrow and reduce the absolute white blood cell count, causing lymphopenia (Bodey et al., 1966; Mackall et al., 1997) . Therefore, amelioration of systemic immunosuppression after chemotherapy is necessary to improve post-chemotherapeutic antitumor immunity.
It is well established that extracellular adenosine inhibits T lymphocyte activation and effector function by signaling primarily through A2A adenosine receptors (A2AR) on the surface of T cells (Ghiringhelli et al., 2012; Raskovalova et al., 2007) . CD39 (ectonucleoside triphosphate diphosphohydrolase 1-Entpd1) hydrolyzes ATP and ADP to AMP. Thereafter, CD73 (ecto-5 0 -nucleotidase-Nt5e) hydrolyzes AMP to adenosine. Chemotherapy induces the massive release of ATP from tumor cells, and the released ATP is hydrolyzed by CD39 and CD73 into adenosine, which impairs antitumor T cell responses.
Extracellular vesicles (EVs), including ectosomes, oncosomes, shedding microvesicles, and microparticles, can regulate immune functions (Wen et al., 2017) . CD73 + EVs from regulatory T cells enhance their suppressive activity by producing adenosine (Smyth et al., 2013) . CD39 + CD73
+ EVs from cancer cells promote the production of extracellular adenosine and negatively regulate T cell function (Clayton et al., 2011) . However, whether CD39 + CD73 + EVs can hydrolyze ATP from chemotherapy-treated tumor cells into adenosine and affect antitumor immunity remains unclear.
Here, we showed that CD19 + EVs from B cells contain high CD39 and CD73, which hydrolyze ATP released by chemotherapy-treated tumor cells into adenosine and attenuate chemotherapeutic efficacy by inhibiting CD8 + T cell responses. HIF-1a enhanced EV generation in B cells by upregulating Rab27a expression in tumor hosts. Silencing of Rab27a by inactivated Epstein-Barr virus (iEBV)-mediated siRNA (small interfering RNA) transfer inhibited CD19 + EV production in B cells and greatly improved the chemotherapeutic effect. Therefore, our findings shed light on the regulation of post-chemotherapeutic T cell responses.
RESULTS

CD19
+ EVs Inhibit CD8 + T Cell Proliferation by Hydrolyzing ATP to Adenosine In Vitro Our previous study had shown that EVs from murine spleens (SpEVs) contain transforming growth factor (TGF)-b1 (Jiang et al., 2016 ). Accordingly, we tested whether Sp-EVs could inhibit CD8 + T cell proliferation in vitro. Sp-EVs were isolated, and their morphology, size distribution, and protein components were characterized (Figures S1A-S1C). Treatment with Sp-EVs failed to alter the CD8 + T cell proliferation ( Figure S1D ). To understand the function of Sp-EVs, we analyzed them by mass spectrometry. Sp-EVs contained high CD39 and CD73 ( Figures 1A-1C ).
In addition, Sp-EVs dose-dependently hydrolyzed ATP, which was mitigated significantly by POM-1 (sodium polyoxotungstate), an inhibitor of CD39 ( Figure 1D ). Sp-EVs also dosedependently hydrolyzed AMP, which was completely abolished by the CD73-specific inhibitor APCP ( Figure 1E ). However, CD39 À CD73 À EVs from NIH-3T3 cells (3T3-EVs; Figure S1E ) did not hydrolyze ATP or AMP ( Figure 1D and 1E). Given that adenosine can inhibit T cell immunity (Ohta et al., 2006) , Sp-EVs may inhibit CD8 + T cell immunity depending on ATP.
Treatment with Sp-EVs, together with different doses of ATP, markedly inhibited CD8 + T cell proliferation in an ATP dosedependent manner (Figures 1F and S1F) that was greatly mitigated by POM-1 and abrogated by APCP. Hence, Sp-EVs inhibit CD8 + T cell proliferation through CD39-and CD73-dependent hydrolysis of ATP into adenosine. Lymphocytes are the most abundant immune cells in the spleen. Both T and B lymphocytes express CD39 and CD73 (Mandapathil et al., 2010; Saze et al., 2013) (I and J) The ATP hydrolytic activity (I) and AMP hydrolytic activity (J) of 30 mg/ml of CD19 + or CD3 + Sp-EVs were measured in vitro (n = 3).
(K) In the presence of 10 mM ATP, the inhibitory effect on the proliferation of CD8 + T cells of 30 mg/ml of CD19 + or CD3 + Sp-EVs were measured in vitro (n = 3).
The data are representative charts (A, B, and G), images (C and H), or values expressed as the mean ± SD of each group (D-F and I-K) from three independent experiments. n indicates biological replicate. *p < 0.05; ***p < 0.001; NS, not significant (Student's t test). See also Figure S1 .
in the presence of ATP (Figures S1G-S1J). Thus, CD19 + EVs from B cells are immunosuppressive by hydrolyzing ATP to adenosine.
CD19 + EVs Reduce the Antitumor Effect of
Chemotherapy through Hydrolyzing ATP to Adenosine Cytotoxic chemotherapy can promote ATP release from tumor cells. We surmised CD19 + EVs could hydrolyze ATP from chemotherapy-treated tumor cells. Similar to a previous report (Martins et al., 2009) , oxaliplatin (OX), doxorubicin (Dox), and phosphoramide mustard (PM), an active metabolite of cyclophosphamide (CTX), remarkably induced ATP release by MC38 colon tumor cells and B16F10 melanoma cells of C57BL/6 mice and 4T1 breast tumor cells of BALB/c mice ( Figure S2A ). CD19 + EVs evidently hydrolyzed ATP released from these cells into adenosine ( Figures S2B and S2C ). Subsequently, we tested whether CD19 + EVs could alter the antitumor effect of chemotherapy through hydrolyzing ATP after chemotherapy ( Figure 2A ). While treatment with CTX prevented the tumor growth and promoted the survival of MC38 tumor-bearing mice, treatment with CTX and CD19 + EVs, but not CTX and CD3 + EVs or CD19 + EVs alone, dose-dependently promoted tumor growth and mouse death ( Figure 2B ). Similar effects of treatment with CD19 + EVs were observed in the CTX-treated B16F10 and 4T1 tumorbearing mice ( Figure 2C ). In addition, CD19 + EVs inhibited the antitumor effect of OX in B16F10 tumor-bearing mice (Figure S2D) . Such data indicated that CD19 + EVs mitigated the chemotherapeutic efficacy in multiple models of murine tumors. Because MC38 cells were the most sensitive to chemotherapy, their serum ATP and adenosine concentrations were measured after chemotherapy. We found that CTX significantly increased serum ATP concentrations, which were reduced by CD19 + EVs ( Figure 2D ). Although CD19 + EVs alone did not increase serum adenosine concentrations, CD19 + EVs enhanced the CTXincreased serum adenosine concentrations ( Figure 2D ). Given that CD39 and CD73 effectively hydrolyzed ATP to adenosine, we tested the role of CD39 or CD73 in CD19 + EV-mediated inhibition on chemotherapeutic efficacy in vivo. Pretreatment of CD19 + EVs with APCP or POM-1 prevented or greatly decreased the inhibition of CD19 + EVs in the antitumor effect of CTX, respectively ( Figure 2E ). Similarly, preincubation of CD19 + EVs with neutralizing antibodies (Abs) against CD73 (anti-CD73) prevented the inhibition of CD19 + EVs in the antitumor effect of CTX ( Figure S2E ). Moreover, CD19 + EVs significantly impaired their inhibition in the antitumor effect of CTX in MC38 tumor-bearing Adora2a fl/fl 3 Er-cre mice that had A2AR deficiency induced by tamoxifen, although tamoxifen alone did not alter the antitumor effect of CTX ( Figure 2F ). These results indicate that CD19 + EVs mitigate chemotherapeutic efficacy through hydrolyzing ATP to adenosine in mice. (D) Longitudinal analysis of the serum ATP and adenosine concentrations in MC38 tumor-bearing mice after the first treatment with CTX and/or CD19 + EVs (n = 3).
(E) Tumor growth (left) and survival (right) of mice that received the same treatment described in (B) with a minor difference. Before i.v. injection, the CD19 + EVs were preincubated with 100 mM APCP or POM-1 for 2 h (n = 5).
(F) Tumor growth (left) and survival (right) of Adora2a fl/fl or Adora2a fl/fl 3 Er-cre mice after CTX and/or CD19 + EVs treatment at the time points shown in (A). In addition, the mice also received i.p. injection with tamoxifen (1 mg/100 ml, on days À3, À2, À1, +10, and +20; n = 5). The data are shown as the mean ± SD of each group from two independent experiments. n indicates biological replicate. *p < 0.05; **p < 0.01; ***p < 0. (Caserta et al., 2012) . Depletion of either CD8 + or CD4 + T cells significantly mitigated the antitumor effect of CTX on MC38 tumor-bearing mice ( Figure 3B ), suggesting the (Figures S3E and S3F) and impair the antitumor effect of CTX in MC38 tumor-bearing mice ( Figure S3G) . However, the plasma and splenic T-CD19 + EVs in tumorbearing mice were significantly higher than those of healthy mice ( Figure 4A ). An increase in the CD19 + EVs may be caused by increased numbers of B cells or the enhanced release of EVs from B cells in tumor-bearing mice. Although the total number of splenic mononuclear cells was significantly increased in tumor-bearing mice, the percentage of B cells was sharply decreased, leading to unchanged absolute numbers of B cells relative to those in healthy mice ( Figure S4A ). Therefore, the increased CD19 + EVs in tumor-bearing mice may be attributed to the enhanced release of EVs from B cells. Because the Rab family proteins smpd3 and tsg101 are crucial for EV release (Kowal et al., 2014) , we analyzed the mRNA transcripts of these genes in B cells from healthy and tumor-bearing mice. We found that the relative amounts of Rab27a and Rab27b mRNA transcripts were significantly higher in tumor B cells than in healthy B cells ( Figure S4B ). Immunoblotting (IB) indicated that Rab27a, but not Rab27b, protein expression was obviously upregulated in tumor B cells ( Figure 4B (K) Quantitative analysis of the results of (J) (n = 3).
(L) The mice were injected subcutaneously with B16F10-OVA tumor cells and were treated with CTX (50 mg/kg) at the time points shown in Figure 2A .
OVA 257-264 -specific CD8 + T cells in TILs were stained with the SIINFEKL tetramer and were analyzed by flow cytometry at 2 weeks post tumor inoculation.
(M) Quantitative analysis of the results of (L) (n = 3).
(N) The serum ATP and adenosine concentrations in the mice of (I) were measured at the indicated time points after the first CTX treatment (n = 3). Figure 4N ). In contrast, treatment with CTX only significantly increased the serum adenosine concentrations in tumor-bearing Rab27a fl/fl mice but not in Rab27a fl/fl 3 Cd19-cre mice ( Figure 4N ). Such data demonstrate that specific inhibition of endogenous CD19 + EVs from B cells remarkably improves CD8 + T cell responses in chemotherapy-treated tumor-bearing mice, likely due to decreased hydrolysis of ATP released from chemotherapy-treated tumor cells into adenosine. B cells can regulate antitumor immunity (Qin et al., 1998 Figure 4O ). Next, we found that CTX still had a great antitumor advantage in B16F10-bearing Rab27a fl/fl 3 Cd19-cre mice that received ISO treatment ( Figure 4P ). CTX similarly inhibited tumor growth in both strains of mice receiving anti-CD73 treatment ( Figure 4P) Figure 5A ). Among the differentially expressed genes (DEGs), those related to the cancer pathway were dramatically enriched ( Figure S6A ). In addition, the genes involved in the HIF-1 signaling were greatly upregulated ( Figures S6A and 5B) . Hypoxia, one of the main characteristics of tumors, can induce HIF-1a expression (Kuo et al., 2017) . Given that HIF-1a increases exosome production in rat renal proximal tubular cells (Zhang et al., 2017) , we tested whether HIF-1a could modulate EV production by B cells. Although there was no significant difference in the relative amounts of Hif1a mRNA transcripts between B cells from healthy and tumor-bearing mice (Figure S6B) , the relative expression of HIF-1a protein was obviously upregulated in tumor B cells ( Figure 5C ). There was no detectable HIF-1a protein expression in T cells from either healthy or tumorbearing mice ( Figure S6C ) and no significant difference in the plasma CD3 + EVs between the healthy and tumor-bearing mice ( Figure S6D ). We found that hypoxia significantly increased the relative amounts of Rab27a mRNA transcripts and protein expression in Raji cells ( Figure 5D ). Induction of HIF-1a overexpression also greatly upregulated Rab27a expression in Raji cells (Figure 5E) . Bioinformatics analysis identified one putative HIF-1a binding site (BS) on the human Rab27a promoter at position À1,563 ( Figure S6E ). Therefore, we determined whether HIF-1a could directly bind to the Rab27a promoter. Chromatin immunoprecipitation (ChIP) revealed that anti-HIF-1a significantly increased the amplification of the Rab27a promoter region in Raji cells cultured under hypoxia, indicating the binding of HIF1a to the Rab27a promoter under hypoxia but not under normal culture conditions ( Figure 5F ). To further determine the regulatory role of HIF-1a, the Rab27a promoter (197 base pairs [bp]) containing the binding sites of HIF-1a or a control fragment of DNA were cloned into a luciferase reporter plasmid as Rab27a-luc or NC-luc, respectively. Subsequently, cotransfection with the plasmid for Hif1a expression and Rab27a-luc, but not empty vector, significantly enhanced the Rab27a-promoter-regulated luciferase activity ( Figure 5G ). These lines of evidence indicate that HIF-1a directly binds to the Rab27a promoter to enhance its transcription. To further determine the role of HIF-1a in EV production by B cells, Raji cells were transfected with negative control (NC) or Rab27a-specific siRNA to silence its expression and then were transfected with a control or Hif1a-overexpressing plasmid. We found that HIF-1a significantly increased EV production in NCtransfected Raji cells but not in Rab27a-silencing Raji cells (Figure 5H) . Such data suggest that HIF-1a promotes EV production in a Rab27a-dependent manner. Similarly, Hif1a fl/fl mice were mated with Cd19-cre mice to obtain Hif1a fl/fl 3 Cd19-cre mice, which had HIF-1a deficiency specifically in B cells but not in T cells ( Figure 5I ). We detected significantly increased plasma and splenic CD19 + EVs in B16F10 tumor-bearing Hif1a fl/fl , but not in Hif1a fl/fl 3 Cd19-cre, mice ( Figure 5J ). In addition, no sig- Cd19-cre mice ( Figure S6F ). These results demonstrate that HIF-1a impaired the antitumor effect of CTX by promoting EV production in tumor B cells by upregulating Rab27a expression.
Increased Serum CD19 + EVs Affect the Chemotherapeutic Efficacy in Cancer Patients
To extend our findings to cancer patients, we detected CD39 and CD73 in serum CD19 + EVs from colon cancer patients (CCP-CD19 + EVs). We found that CCP-CD19 + EVs carried high CD39 and CD73 ( Figure 6A ) and effectively hydrolyzed ATP into adenosine ( Figures 6B and 6C) . Furthermore, CCP-CD19 + EVs significantly inhibited the proliferation of peripheral blood CD8 + T cells in the presence of ATP ( Figure 6D ). EVs from Raji cells (Ra-EVs) displayed similar characteristics and function (Figures 6A-6D ). In addition, the serum CD19 + EVs in gastric and colon cancer patients (GCPs and CCPs), regardless of cancer stage, were significantly higher than those in healthy controls (HC; Tables S1 and S2; Figure 6E ). The serum CD19 + EVs before chemotherapy were negatively correlated with the progressionfree survival period (PFSP) in 48 GCPs and 20 CCPs (Tables S3  and S4 ; Figure 6F ). Stratification analysis indicated that the patients with lower serum CD19 + EVs had significantly longer PFSPs ( Figure 6G ). Moreover, surgical removal of tumors reduced the serum CD19 + EVs in most of the 22 GCPs and 17 CCPs (Table S5 ; Figure 6H ). These results indicate that CD19 + EV production by B cells increased in patients with different types of cancers, impairing the chemotherapeutic efficacy.
Specific Silencing of Rab27a in B Cells by iEBV-Rab27a siRNA Improves the Chemotherapeutic Efficacy Given that the inhibition of endogenous EV production by B cells effectively improved the chemotherapeutic effect in mice, we further explored the impact of Rab27a silencing, specifically in B cells to inhibit their EV production, on the chemotherapeutic effect in severely immuno-compromised NOD (non-obese diabetic) Prkdc scid Il2rg À/À (NSG) mice. Because EBVs can specifically infect B cells with a high efficiency (Pattengale et al., 1973) , we tested whether iEBVs could carry Rab27a siRNA. We found that iEBVs dose-dependently carried Rab27a siRNA (iEBVs-Rab27a siRNA) ( Figure S7A ). The iEBVs-Rab27a siRNA effectively transferred Rab27a siRNA ( Figure S7B ), silenced Rab27a expression, and reduced EV production in Raji cells ( Figures S7C and S7D) . Similarly, transfection with iEBVs-Rab27a siRNA obviously decreased Rab27a expression in primary B cells from healthy subjects ( Figure 7A ). Accordingly, we tested the effect of treatment with iEBVs-Rab27a siRNA on Rab27a expression in B cells in vivo. After reconstruction of the human immune system in NSG mice ( Figure S7E ), we found that iEBVs-Rab27a siRNA specifically transfected human B cells ( Figure S7F ). iEBVs-Rab27a siRNA, but not NC siRNA-carrying iEBVs (iEBVs-NC siRNA), reduced Rab27a expression in human splenic in situ B cells ( Figure 7B ) and in human B cells from humanized NSG mice ( Figures S7G and S7H) . Treatment with iEBVs-Rab27a siRNA, but not with iEBVs-NC siRNA, significantly reduced the serum CD19 + EVs in humanized NSG mice ( Figure 7C ). Hence, iEBVs-Rab27a siRNA specifically downregulated Rab27a expression in human B cells and subsequent EV production in vivo. Finally, we determined whether iEBVs-Rab27a siRNA could affect the antitumor effect of chemotherapy. NSG and humanized NSG mice were inoculated subcutaneously (s.c.) with human colon cancer Lovo cells and treated with or without CTX and iEBVs or iEBVs-Rab27a siRNA ( Figure 7D ). Compared with NSG mice, humanized NSG mice displayed slightly reduced tumor volumes, suggesting the constructed human immunity against tumor growth ( Figure 7E ). In addition, treatment with iEBVs did not affect the antitumor effect of CTX in humanized NSG mice ( Figure 7E ). Treatment with either iEBVs-Rab27a siRNA or iEBVs-NC siRNA failed to alter the tumor growth in the absence of CTX ( Figure 7F) . Notably, treatment with iEBVs-Rab27a siRNA, but not with iEBVs-NC siRNA, greatly inhibited tumor growth and prolonged the survival of tumor-bearing humanized NSG mice after CTX treatment (Figure 7F ). In addition, treatment with iEBVs-Rab27a siRNA and CTX significantly increased CD8 + T cells in the TILs of tumorbearing humanized NSG mice ( Figures 7G and 7H) . Finally, treatment with iEBVs-Rab27a siRNA and CTX maintained a higher concentration of serum ATP in tumor-bearing mice at 24 h posttreatment but did not increase the concentrations of serum adenosine ( Figure 7I ). Therefore, iEBVs-Rab27a siRNA may be a promising tool to reduce CD19 + EV production in B cells and to enhance the antitumor effect of chemotherapy and CD8 + T cell responses. Tables S1-S5 .
t test (B-E and H); Spearman's rank-order correlation test (F); log-rank test (G). See also
DISCUSSION
Although various cancer immunotherapies have emerged (Wang, 2017) , chemotherapy remains one of the most effective treatments for advanced cancers (Benevento et al., 2017; Menna and Salvatorelli, 2017) . However, chemotherapeutic drugs usually cause immunosuppression, which impairs their antitumor effects. Adenosine, a negative regulator of immune responses, can preferably induce immune deviation, such as M2-like macrophages; promote regulatory immune responses; and inhibit T cell activation and proliferation (Ghiringhelli et al., 2012 The data are representative images (A, B, and G) or are expressed as the mean ± SD of each group (C, E, F, H, and I) from two independent experiments. n indicates biological replicate. *p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant; Student's t test (C; E, left; F, left; H; and I); log-rank test (E, right and F, right); versus the humanized NSG in (E) and versus the CTX + iEBVs-Rab27a siRNA in (F). See also (Clayton et al., 2011; Deaglio et al., 2007; Saze et al., 2013) . However, unlike immune cells, which require specific chemokines and their receptors to migrate into the tumor environment, EVs, because of their size advantage, can effectively enter the tumor environment by passing through impermeable biological barriers (Lakhal and Wood, 2011) . Hence, EVs from cancer cells have natural superiority and may be more important in hydrolyzing ATP in the tumor environment. Notably, chemotherapeutic drugs can cause massive tumor cell apoptosis and release substantial ATP into the systemic circulation, where ATP is hydrolyzed by CD19 + EVs. Thus, CD19 + EVs may be one of the main executors to hydrolyze ATP into adenosine in tumor hosts after intensive chemotherapies. Smpd3, Rab27a, and Rab27b are crucial for EV production (Ostrowski et al., 2010; Trajkovic et al., 2008) . In B cells, Rab27a, but not Rab27b or smpd3, controls EV production. Evidently, Rab27a silencing decreased EV production in B cells, and Rab27a À/À in B cells also abrogated the tumor-increased EV production by B cells in Rab27a fl/fl 3 Cd19-cre mice. Furthermore, we revealed that HIF-1a is the critical transcription factor to induce Rab27a transcription and that CD19 + EVs were increased in tumor-bearing wild-type mice but not in tumorbearing Hif1a fl/fl 3 Cd19-cre mice. We detected upregulated HIF-1a in splenic B cells from tumor-bearing mice. Although hypoxia frequently occurs in the tumor microenvironment, splenic B cells are less likely to be in a hypoxic condition. Tumors have a unique metabolic characteristic termed the Warburg effect. Even with sufficient oxygen, cancer cells preferentially perform aerobic glycolysis, leading to the conversion of most glucose molecules into lactic acid (Warburg, 1956) . Tumorderived lactic acid has been demonstrated to stabilize HIF-1a protein under normoxia, mediating functional polarization of tumor-associated macrophages (Colegio et al., 2014) . Therefore, HIF-1a in splenic B cells is probably upregulated by tumor-derived lactic acid but not hypoxia itself.
We found that treatment with exogenous CD19 + EVs attenuated the antitumor effect of chemotherapy, whereas specific silencing of Rab27a in B cells to inhibit their EV production enhanced the antitumor effect of chemotherapy in vivo. T cells is present in patients, the combination of chemotherapy and iEBVs-Rab27a siRNA may be a promising strategy to eradicate tumors. Although anti-CD73 treatment also enhanced the chemotherapeutic effect in mice, anti-CD73 may not be safe for clinical practice because CD73 is crucial for extravasation and cardioprotection (Bö nner et al., 2013; Salmi and Jalkanen, 2005) . This, together with the common side effects of monoclonal antibody therapy, may impede the clinical application of anti-CD73. We found higher serum CD19 + EVs in tumor patients, even in those with early stages of tumors. Furthermore, patients with lower serum CD19 + EVs had longer PFSPs after chemotherapy, and the surgical removal of tumors greatly reduced the serum CD19 + EVs in patients. Hence, the detection of abnormally high serum CD19 + EVs may be valuable for the diagnosis, prognosis, and evaluation of the therapeutic efficacy in tumor patients. Altogether, our findings reveal a mechanism by which tumor cells escape from immune surveillance after chemotherapy and may aid in the design of antitumor therapies.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: fl/fl mice were kindly provided by Prof. Liu Guangwei (Fudan University, Shanghai, China). The mice were housed in a specific pathogen-free facility, and the experimental protocols were approved by the Animal Care and Use Committee of the School of Medicine, Zhejiang University. Human colon cancer Lovo, human embryonic kidney 293T, murine melanoma B16F10, colon cancer MC38, breast cancer 4T1, and fibroblast NIH-3T3 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human Burkitt lymphoma Raji cells and EBV-producing monkey B95-8 cells were purchased from the Chinese Academy of Sciences (Shanghai, China). Murine MC38-OVA cells were established in our laboratory. B16F10, MC38, and NIH-3T3 cells were cultured in EV-free DMEM supplemented with 10% fetal bovine serum (FBS); 4T1, Raji, and B95-8 cells were maintained in EV-free RPMI 1640 medium supplemented with 10% FBS. All cells were incubated at 37 C in a humidified atmosphere of 5% CO 2 -95% air.
METHOD DETAILS EV Isolation
To isolate Sp-EVs, spleen tissues were dissected from unmanipulated C57BL/6 mice and were gently ground in PBS, followed by centrifugation at 300 3 g for 10 min. The supernatants were collected and filtered through a 0.22-mm filter. To isolate B-EVs, murine B cells were isolated by negative selection using the Mouse B Cell Isolation Kit according to the manufacturer's instructions. The B cells were stimulated with 10 mg/ml of LPS and 25 ng/ml of IL-4 for 3 days, and their culture supernatants were collected. Subsequently, the tissue or cell culture supernatants were differentially centrifuged at 300 3 g for 10 min, 2,000 3 g for 20 min, and 10,000 3 g for 30 min at 4 C. The supernatants from the final centrifugation were ultracentrifuged at 100,000 3 g for 1 h at 4 C. The pellets were washed with a large volume of ice-cold PBS and were centrifuged at 100,000 3 g for another 1 h at 4 C. The final pellets were resuspended in PBS. The concentrations of EV proteins were measured using the BCA Protein Assay Kit.
Electron Microscopy and Nanoparticle Analysis
EVs were placed on 200-mesh carbon-coated copper grids at RT for 2 min. The excess suspension was removed using filter paper. The EVs were negatively stained with uranyl acetate at RT for 5 min, washed twice with PBS and dried. The EVs were examined under an FEI Tecnai T10 electron microscopy operating at 100 kV, and their images were captured. The size distribution of EVs was analyzed using the qNano Gold Particle Sizing Instrument (Izon Science, OX, UK).
Mass Spectrometry Analysis of Sp-EVs
A total of 100 mg of Sp-EVs was concentrated by SDS spacer gel and was cut into 0.6 mm 3 0.3 mm gel pieces. The contents of proteins were analyzed by mass spectrometry using the Q Exactive system (Thermo Scientific) by Beijing Protein Innovation (Beijing, China). The spectra were automatically used for searching against the UniProt database.
IB
A total of 30 mg of EVs or cell lysate proteins was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 12% gels and was transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 5% BSA in TBST buffer and were incubated with primary Abs overnight at 4 C. After washing, the bound Abs were detected with horseradish peroxidase (HRP)-conjugated secondary Abs for 1 h and were visualized using enhanced chemiluminescent reagents, followed by scanning in a Tanon 4500 Gel Imaging System.
Flow Cytometry
For EV or iEBV flow cytometry analysis, EVs or iEBVs were coated onto 4-mm-diameter aldehyde-sulfate latex beads, as described previously (Jiang et al., 2016) . The EV-coated beads were stained with the corresponding fluorescence-labeled Abs for 30 min on ice. For semiquantitative analysis of EVs, anti-mouse CD63 Abs were coupled to the latex beads, in which 1 3 10 8 were incubated with 20 mg of EVs, followed by blocking with FBS. Raji cells (2 3 10 6 /well) were cultured in 12-well plates in 1 ml of RPMI 1640 with 10%
FBS and were transfected with NC siRNA, Rab27a or Hif1a-specific siRNA for 24 h. The supernatants were collected and filtered through 0.22-mm filters. The filtrates (500 ml) were incubated with 20,000 anti-CD63-coupled beads overnight at RT with gently shaking. After being washed, the beads were incubated with PE-conjugated anti-CD9 Abs for 30 min on ice. For cell surface staining, cells were washed with PBS twice and incubated with the corresponding fluorescence Abs for 30 min on ice. For intracellular staining, cells were stimulated with PMA (50 ng/ml) and Ionomycin (1 mg/ml) for 4 h at 37 C and then cells were conducted as intracellular staining protocol. Finally, after being washed with PBS twice, all the events were harvested and analyzed by flow cytometry. Data were analysed using FlowJo software (Tree Star, Ashland, OR, USA).
Isolation of CD3
+ or CD19 + EVs To isolate CD3 + or CD19 + EVs, 200 mg of Sp-EVs was incubated with biotinylated anti-CD3 or anti-CD19 (final concentration 1 mg/ml)
for 4 h at room temperature (RT) with gentle shaking and was mixed with 40 ml of MagniSortÔ Streptavidin Positive Selection Beads overnight at 4 C with gentle shaking. The CD3 + or CD19 + EVs were isolated using a magnet. The bead-free supernatants containing CD3
-or CD19 -EVs were collected. Subsequently, the collected individual types of EVs were subjected to centrifugation at 100,000 3 g for 1 h. The pellets were resuspended in PBS. The CD3 + or CD19 + EVs were detached from the beads using the CELLectionÔ Biotin Binder Kit, according to the manufacturer's instructions.
CD8 + T Cell Proliferation Assay
Mouse or human CD8 + T cells were isolated from splenocytes or human PBMCs by negative selection using the Mouse CD8 + T cells Isolation Kit or Human CD8 + T Cell Enrichment Kit, according to the manufacturer's instructions, respectively. The CD8 + T cells were labeled with CFSE and were cultured at a density of 2 3 10 6 /ml into 96-well plates. The cells were stimulated with 1 ml of anti-mouse or human anti-CD3 and CD28-coated Dynabeads for 3 days. To evaluate the effect of EVs on T cell proliferation, CD8 + T cells were stimulated with anti-CD3 and CD28 beads in the presence or absence of 3, 10, or 30 mg/ml Sp-EVs, or 30 mg/ml CD19 + EVs, CD3 + EVs, 3T3-EVs, CCP-CD19 + EVs, Ra-EVs, or B-EVs with, or without, 10 mM ATP. In some experiments, the CD8 + T cells were stimulated in the presence of 100 mM POM-1 or APCP. Three days later, the cells were harvested and analyzed by flow cytometry.
Measurement of the ATP and AMP Hydrolytic Activity of EVs
To detect the ATP and AMP hydrolytic activity of EVs, EVs were repelleted by ultracentrifugation and resuspended in MES buffer to remove inorganic phosphate in PBS. Subsequently, 3, 10 or 30 mg/ml Sp-EVs, 30 mg/ml CD19 + EVs, CD3 + EVs, 3T3-EVs, CCP-CD19 + EVs, Ra-EVs, or B-EVs were reacted with 20 mM ATP or AMP in 500 ml of MES for 1 h. The concentrations of ATP and inorganic phosphate produced by ATP or AMP were quantified using the ATP Assay Kit and SensoLyte MG Phosphate Assay Kit, respectively. The concentrations of adenosine produced by ATP or AMP were measured using the Adenosine Assay Kit. All measurements were performed according to the manufacturer's protocol. To detect the activity of CD19 + EVs to hydrolyze ATP released from tumor cells after treatment with OX, Dox or PM, tumor cells (8 3 10 4 cells in 1 ml volume) were cultured in 24-well plates and were treated with 30 mM OX, Dox, or 10 mM PM for 18 h. Next, the supernatants were collected. Individual supernatant samples (500 ml each) were mixed with 20 mg of CD19 + EVs for 1 h. Subsequently, the concentrations of ATP and adenosine in the supernatants were measured as described above.
Tumor Models and Treatments
Individual mice were injected s.c. with 2 3 10 6 MC38 or MC38-OVA, 8 3 10 5 B16F10, or 1 3 10 6 4T1 cells on day 0. The tumorbearing mice were randomized and injected i.p. with CTX (50 mg/kg) or OX (20 mg/kg) on days +5, +10, +15 and +20 postinoculation. In addition, some tumor-bearing mice were treated i.v. with 80 mg of CD19 + EVs on days +6, +11, +16, and +21 postinoculation. In some experiments, CD19 + EVs were preincubated with 100 mM APCP or POM-1, or 30 mg of anti-mouse CD73 Abs for 2 h. To silence A2AR, Adora2a fl/fl 3Er-cre mice were treated i.p. with tamoxifen in olive oil (1 mg/100 ml) on days -3, -2, -1, +10, and +20 postinoculation. To delete CD4 + or CD8 + T cells, individual mice were injected i.p. with anti-mouse CD4 or anti-mouse CD8 Abs (100 mg/100 ml) on days +4, +6, +8, +10, and +12 postinoculation.
Real-Time PCR Total RNA was extracted using TRIzol reagent and was reverse transcribed into cDNA using the cDNA Synthesis Kit, according to the manufacturer's instructions. Real-time PCR was performed using the SYBR Premix Ex Taq and specific primers in the Applied BIO-RAD real-time PCR system. The PCR conditions were 1 cycle at 95 C for 30 s and 40 cycles of 5 s at 95 C and 34 s at 60 C. The data were analyzed by 2 -DDCt .
Plasmid and siRNA Transfection Raji, 293T and NIH-3T3 cells were transfected with plasmids using the JetPEI Ò Transfection Reagent, according to the manufacturer's protocol. Raji cells were transfected with scramble NC or targeted siRNA using the TransIT-TKO Transfection Reagent, according to the manufacturer's instructions.
Luciferase Reporter Assay
The sequence of the human Rab27a gene promoter region, from position -1561 bp $ -1365 bp was amplified from Raji genomic DNA by PCR and was cloned into the pGL3 luciferase reporter vector. 293T cells were transfected with Rab27a-luc, along with the plasmid for Hif1a expression and pRL-cytomegalovirus using the JetPEI Transfection Reagent for 24 h. The luciferase activity in cell lysates was detected using a Dual-luciferase Reporter Assay System, and the data were normalized to Renilla luciferase activity. Empty pCRcytomegalovirus vector was used as the control.
RNA-Seq Analysis
Total RNA was isolated and reverse transcribed into cDNA to generate indexed Illumina library, followed by sequencing at the Beijing Genomics Institute (Beijing, China) using a BGISEQ-500 platform. High-quality reads were aligned to the mouse reference genome (GRCm38) by Bowtie2. The expression of individual genes was normalized to fragments per kilobase of the exon model per million mapped reads from RNA-Seq by Expectation Maximization. Significant differential expression was set if a gene with > 2-fold expression difference versus the control with adjusted p-value of < 0.05. The DEGs were analyzed by gene ontology using AMIGO and DAVID software. The enrichment degrees of DEGs were analyzed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) annotations.
ChIP Assay
The ChIP assay was performed using a ChIP Assay Kit, according to the manufacturer's instructions with minor modifications. Briefly, Raji cells were cultured regularly or in a hypoxic (94% N 2 -5% CO 2 -1% O 2 ) chamber for 4 h. The proteins and DNA were crosslinked by 1% formaldehyde for 10 min at RT. The DNA was sheared by Bioruptor Pico (Diagenode) for 16 cycles to obtain chromatin fragments of 200$500 bps. The corresponding lysates were incubated and immunoprecipitated with anti-HIF-1a Abs. The precipitated DNA fragments were quantified by real-time PCR. The HIF-1a at the Rab27a promoter were expressed as a percentage of the total input DNA.
Isolation of TILs
Tumors were dissected from mice and were digested with collagenase IV (1 mg/ml) and DNase I (20 mg/ml) in RPMI 1640 medium for 2 h at 37 C with gentle shaking. The mixtures were diluted and filtered. The TILs in the tumor cell suspension were separated by the Mouse 1 3 Lymphocyte Separation Medium. After washing, the cells were used for subsequent experiments.
Measurement of the Serum CD19 + EVs
The serum CD19 + EVs in individual samples were determined by sandwich ELISA. Briefly, 96-well ELISA plates were coated with antiRab5b Abs overnight (4 mg/ml, 25 ml), and, after being washed, each well was added in duplicate with serum samples (50 ml/sample), followed by incubation overnight at 37 C. The plates were washed, and the bound EVs were detected with 25 ml of biotinylated anti-CD19 Abs (4 mg/ml) for 1 h at 37 C. After being washed, individual wells were added with 25 ml of avidin-HRP for 1 h at RT. Subsequently, the reaction was developed with TMB and blocked with 2 M H 2 SO 4 , followed by measurement of the absorbance at 450 nm.
Purification and Inactivation of EBVs
The supernatants of cultured B95-8 cells were collected and centrifuged sequentially at 300 3 g for 10 min, 2,000 3 g for 20 min, and 10,000 3 g for 30 min at 4 C. The supernatants were ultracentrifuged at 38,000 g for 1 h at 4 C. The EBV pellets were washed with ice-cold PBS, centrifuged and resuspended in PBS. The obtained viruses were inactivated with ultraviolet irradiation for 1 h at RT and quantified by the BCA Protein Assay Kit. The viruses were aliquoted for storage at À80 C.
Package of Rab27a siRNA into iEBVs Sixty-six micrograms of NC or Rab27a siRNA were incubated with 300 mg of iEBVs at 37 C for 2 h, followed by centrifugation at 38,000 g for 1 h at 4 C twice. The iEBV pellets were resuspended in PBS.
Silencing of Rab27a in Raji and Human Primary B cells by iEBVs-Rab27a siRNA Human primary B cells were isolated from PBMCs using the Human CD19 Positive Selection Kit. The B cells or Raji cells (2 3 10 6 in 2 ml) were cultured in 12-well plates and were transfected with 100 mg of iEBVs-Rab27a siRNA for 48 h. The efficacy of Rab27a silencing was determined by IB.
Generation of Humanized NSG Mice, Induction of Tumors and Treatment
Human umbilical cord blood CD34 + stem cells were isolated using the Human CD34 Positive Selection Kit, according to the manufacturer's instructions. Individual NSG mice were irradiated for 1.5 Gy and were injected i.v. with 5 3 10 5 CD34 + stem cells. Two months later, the mice were injected s.c. with 2.5 3 10 6 Lovo cells on day 0. The mice were randomized and injected i.v. with 300 mg of iEBVs-NC or iEBVs-Rab27a siRNA on days +3, +8, +13, and +18. In addition, the mice were injected i.v. with CTX (50 mg/kg) on days +5, +9, and +13.
QUANTIFICATION AND STATISTICAL ANALYSIS
The data are expressed as mean ± SD. The survival rate and Pearson's correlation were analyzed by the log-rank test and Spearman rank-order correlation test, respectively. All other results were analyzed by unpaired Student's t test. Statistical analysis was performed using Graph Prism 7.0 software, and p < 0.05 was considered to be statistically significant.
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